GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Goodwill

GYRE (Gyre Therapeutics) Goodwill : $0.0 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Goodwill?

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Gyre Therapeutics's goodwill for the quarter that ended in Dec. 2024 was $0.0 Mil.


Gyre Therapeutics Goodwill Historical Data

The historical data trend for Gyre Therapeutics's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Goodwill Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Goodwill
- - - -

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Gyre Therapeutics Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.


Gyre Therapeutics  (NAS:GYRE) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Gyre Therapeutics's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Goodwill-to-Asset (A: Dec. 2024 )=Goodwill/Total Assets
=0/125.406
=0.00

Gyre Therapeutics's Goodwill-to-Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Goodwill-to-Asset (Q: Dec. 2024 )=Goodwill/Total Assets
=0/125.406
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Gyre Therapeutics Goodwill Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.


Gyre Therapeutics Business Description

Traded in Other Exchanges
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.